Peter Riedell, MD

home / authors / peter-riedell-md

Articles

Peter Riedell, MD

Dr. Riedell on the Clinical Utility of EZH2 Mutation Testing in Relapsed/Refractory FL

September 19th 2023

Peter Riedell, MD, discusses the clinical utility of EZH2 mutation testing when navigating treatment options for patients with relapsed/refractory follicular lymphoma.

Read More

Peter Riedell, MD

Dr. Riedell on the Examination of Axi-Cel Therapy in High-Risk LBCL

April 25th 2022

Peter Riedell, MD, discusses the use of axicabtagene ciloleucel in high-risk large B-cell lymphoma, as evaluated on the phase 2 ZUMA-12 trial.

Read More

Peter Riedell, MD

Dr. Riedell on Unique Data Points from an Analysis in MCL

January 11th 2022

Peter Riedell, MD, discusses unique data points of a landmark analysis conducted in mantle cell lymphoma.

Read More

Peter Riedell, MD

Dr. Riedell on an Analysis Evaluating the Effect of Time to Relapse on OS in MCL

December 22nd 2021

Peter Riedell, MD, discusses the patient population and design of a dynamic landmark analysis conducted in patients with mantle cell lymphoma.

Read More

Peter Riedell, MD

Dr. Riedell on the Effects of Time to Relapse on Outcomes in MCL

December 21st 2021

Peter Riedell, MD, discusses the effects of time to relapse on outcomes in mantle cell lymphoma.

Read More

Peter Riedell, MD

Dr. Riedell on the Rationale to Evaluate Survival Outcomes After Transplant in MCL

September 23rd 2021

Peter Riedell, MD, discusses the rationale to evaluate survival outcomes after transplant in mantle cell lymphoma.

Read More